RENBP and hyperlipidemia: Overall, these data highlighted that the metabolic pathway alterations might be the potential targets of PSO when treating hyperlipidemia, especially the lipid and atherosclerosis pathway (hsa05417), PI3K-Akt signaling pathway (hsa04151), and AGE-RAGE signaling pathway (hsa04933).